SHAREHOLDER ACTION NOTICE: Schall Law Firm Encourages Investors in TG Therapeutics, Inc. with $100,000 Losses to Contact the Firm

LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against TG Therapeutics, Inc. (“TG Therapeutics” or “the Company”) (NASDAQ: TGTX) for violation of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the United States Securities and Exchange Commission.

Investors who purchased the Company’s securities between January 15, 2020 and May 31, 2022 inclusive (the “Class Period”) are invited to contact the Company before September 16, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us via the firm’s website at www.schallfirm.com or by e-mail at [email protected]

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to do nothing, you can remain an absent member of the group.

According to the complaint, the company made false and misleading statements to the market. TG Therapeutics’ clinical trials of Ublituximab and Umbralisib have revealed concerns about the benefit/risk ratio and overall survival data for the drugs. Based on these issues, the company was unlikely to obtain FDA approval for Umbralisib MZL/FL NDA, U2 BLA, U2 sNDA, or Ublituximab RMS BLA in their current form. The Company exaggerated the market prospects of Ublituximab and Umbralisib. Based on these facts, the Company’s public statements were false and materially misleading throughout the Class Period. When the market learned the truth about TG Therapeutics, investors suffered damage.

Join the case to recoup your losses.

Schall Law Firm represents investors worldwide and specializes in securities class action and shareholder rights litigation.

This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethical requirements.

Comments are closed.